NGF and Alzheimer disease: A follow-up phase 2 multicenter, sham surgery-controlled clinical trial of NGF in AD used adeno-associated virus serotype 2 (AAV2) vectors to directly express NGF in cholinergic regions of the cholinergic basal forebrain [6].